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Abstract The goal of this study was to determine com-
pliance with oﬃcial recommendations for prevention of
perinatal hepatitis B virus transmission from hepatitis B
surface antigen (HBsAg) positive mothers to their oﬀ-
spring. All infants born to HBsAg positive mothers at
the University Women’s Hospital in Basel, Switzerland,
in 2001 were identiﬁed and post-exposure immunisations
were analysed. In addition, detailed written information
on subsequent hepatitis B immunisations was obtained
from the infants’ paediatricians. A total of 1513 women
gave birth to 1554 children and screening for HBsAg
had been performed in 1503 (99%) women, of whom 8%
were screened during delivery. A group of 18 (1.2%)
women were HBsAg positive and 17 (95%) of the 19
exposed infants promptly received active and passive
immunisation. One exposed infant was lost to follow-up
and in one, postnatal vaccination was missed. Of the
remaining 17 exposed infants, 9 (53%) received the full
course of three active immunisations, but only two
(12%) were immunised within the recommended time
frame. On follow-up, six children were still too young
for serological testing for successful immunisation.
Among the remaining 11 immunised infants,
serological testing had been performed in 4 (36%).
Conclusion: Compliance with recommendations for
hepatitis B surface antigen screening was excellent in this
study. The proportion of exposed infants receiving all
three active immunisations was satisfactory, but more
attention must be paid to complete and timely
administration and serological testing in the future. This
will require improved communication between neona-
tology units and care-providing paediatricians in private
practices.
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Introduction
An estimated 2 billion people world wide are infected
with the hepatitis B virus, of whom 350 million suﬀer
from chronic disease [11]. About 25% of chronically ill
patients will develop progressive liver disease with
cirrhosis and an additional risk of hepatocellular carci-
noma [16]. Furthermore, about one million people die
every year from sequelae of chronic hepatitis. The
frequency of hepatitis B surface antigen (HBsAg)
carriers in Switzerland is estimated to be 0.3% (0.5% in
women of child-bearing age) which equals a prevalence
of approximately 20000 individuals with chronic disease
[3, 12].
The risk of vertical transmission of hepatitis B virus
during birth and the subsequent development of chronic
disease is approximately 90% in untreated oﬀspring of
HBsAg and hepatitis B envelope antigen (HBeAg)
positive mothers [2] and 40% in those born to HBsAg
positive, HBeAg negative mothers [13]. In light of this
signiﬁcant morbidity, the Swiss Federal Health Oﬃce
has recommended antenatal hepatitis B screening for all
pregnant women followed by active and passive immu-
nisation of all infants born to HBsAg positive mothers
since 1997 [3]. If screening has not been performed
before birth, an emergency screening test should take
place during or shortly after birth. The objective is to
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identify those infants in need for immunoprophylaxis as
soon as possible (preferable within 12 h) in order to
prevent infection. This procedure has a success rate of
90%–97% and also provides long-lasting immunity
[6, 7]. For completion of the immunisation series, two
further doses of hepatitis B vaccine (HBV) are recom-
mended at 1 and 6 months of age. Supplementary
serological control of successful immunisation of the
infant is recommended at the age of 9–15 months as an
aid in the long-term medical management of the few
vaccine failures in patients who become infected.
The goal of the present study was to determine
compliance with oﬃcial recommendations to prevent
perinatal hepatitis B transmission in infants born at the
University Women’s Hospital in Basel, Switzerland.
Subjects and methods
Data collection
In this retrospective study, records of all women
admitted for delivery to the University Women’s Hos-
pital in Basel between January 1 and December 31, 2001,
were identiﬁed. The following data were extracted from
the patient records: mother and child’s date of birth,
maternal nationality and HBsAg status. Additional
demographic information was collected if the mother
was HBsAg positive: full names of mother and child,
address and home phone number (if available), and
name of the paediatrician selected for further care.
Moreover, the exact time interval of administration of
hepatitis B immunoglobulin (HBIG) and/or HBV after
birth was assessed. The child’s discharge letter was
evaluated for speciﬁc details on the HBsAg positive
status of the mother, immunisation procedures while in
hospital, and recommendations regarding the need for
completion of the immunisation series as well as sub-
sequent serological monitoring.
Informed consent was obtained from all HBsAg po-
sitive mothers to contact their child’s paediatrician.
Then, a standardised questionnaire was sent to the
paediatricians to obtain information on number and
dates of any subsequent hepatitis B immunisations in the
individual children and results of subsequent serological
monitoring.
This investigation was approved by the ethics com-
mittee of the University of Basel Medical Faculty.
Data analysis
In accordance with the Swiss national guidelines for
prevention of hepatitis B in newborns of HBsAg positive
mothers [3], parameters assessed were categorised as
‘‘complete and on time’’ if: HBIG was administered
within the ﬁrst 12 h of birth and a ﬁrst dose of HBV was
administered within 12 h and was followed by a second
dose of HBV at 4 (-6) weeks of age and a third dose of
HBV at 6 months of age (+/-2 weeks). Alternatively, if
the interval between the second and third immunisation
was less than 2 months, a fourth dose of HBV was
necessary (0–1-2–12 month schedule). Furthermore, a
serum sample was to be taken at 9–15 months of age to
determine the level of anti-HBs antibodies and to ex-
clude chronic infection by determining the HBsAg status
of the child. An anti-HBs antibody level of ‡100 mIU/
ml is considered to correlate with long-term protection
from hepatitis B. In the case of anti-HBs levels
<100 mIU/ml, further dose(s) of active immunisation
should be considered.
Statistical analysis
Statistical analyses were performed using the SPSS
package version 10.0 (SPSS Inc., Chicago).
Results
Maternal characteristics
In 2001, a total of 1513 women gave birth to 1554 in-
fants at the University Women’s Hospital, Basel. Of
these 1513 women, 699 (46%) were Swiss and 812 (54%)
were of foreign nationality. We were unable to deter-
mine the nationality in two women. In 1387 (91.7%)
women, HBsAg testing was performed as part of ante-
natal care and in 116 women (7.7%) screening was only
performed at delivery. Ten women (0.7%) did not un-
dergo any screening at all. None of the children born to
these ten women received immunoprophylaxis.
Of the 1503 screened women, 18 (1.2%; 95% CI:
0.65–1.75) were HBsAg positive, including 2 of those
116 (2%) screened during delivery. HBeAg status was
tested in six (33%) HBsAg positive women and one was
found to be HBeAg positive. Of the 18 HBsAg positive
women, 5 were Swiss, 10 were Turkish and 3 came from
former Yugoslavia with nationality dependent preva-
lence rates of 0.7%, 5.7% and 2.4%, respectively. None
of 77 Asian and 54 African women were HBsAg posi-
tive.
Immunoprophylaxis in exposed infants after delivery
A total of 19 infants were born to 18 HBsAg positive
mothers. One infant was lost to follow-up. Of the
remaining 18 infants (11 girls, 7 boys), 17 received HBIG
and HBV during hospital stay; 15 (83%) infants received
HBIG and 14 (78%) received a ﬁrst dose of HBV within
12 h after birth, respectively. In two cases, administra-
tion of HBIG and active immunisation was delayed by
24–48 h, including one child whose mother had only
been screened during delivery. One premature infant
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(24th gestational week) was initially given HBIG and
only at the age of 2 months was the ﬁrst dose of HBV
administered. In one newborn, the positive maternal
HBsAg status was overlooked and therefore no immu-
noprophylaxis was administered. Unfortunately, acute
hepatitis B infection (positive tests for HBsAg, Anti-
HBc IgM and –IgG) was diagnosed in this child at the
age of 5 months and further serological testing at 1 and 2
years of age revealed persistence of HBsAg, indicating
chronic hepatitis B infection.
Information included in discharge letters
Discharge letters to the paediatricians of those 18
exposed children who had received hepatitis B immu-
noprophylaxis were analysed. Sixteen letters included
information on the positive HBsAg status of the mother
and the performed active and passive immunisation.
Nine letters also included instructions to complete the
active immunisation series after 1 and 6 months. No
letter mentioned the recommendation of serological
testing after completion of the immunisation series.
Completion of immunisation and serological follow-up
Of 17 exposed infants, 9 (53%) had received a complete
series of active immunisation, but only 2 (12%) had been
immunised strictly according to the recommended
schedule at 0, 1 and 6 months of age (Fig. 1). One child
had received an additional fourth dose at 15 months of
age.
In ten infants, where immunisation had been initiated
according to the three-dose schedule, the second dose of
HBV was delayed by 2–8 months and in those who had
already received the third dose, this was delayed by a
further 1–5 months. In ﬁve infants immunised according
to the four-dose schedule, the second and third dose of
HBV were administered on time.
At the time of data analysis, eight infants had not yet
received the full number of recommended doses and
completion was enforced by our communication with
the respective paediatricians. Furthermore, 11 of 18 ex-
posed infants were between 9 and 16 months of age and
4 of them had been fully immunised. In one child,
serological testing had been performed by the paedia-
trician and serum specimens were obtained in further
three infants on our initiative. Anti-Hbs antibody values
were ‡100 mIU/ml in all four children.
Discussion
In the western world, morbidity and mortality of hepa-
titis B virus infection primarily results from chronic
infection which occurs at highest risk (90%) with
infections acquired perinatally or early in the postnatal
period. In contrast, intra-uterine infections are rare.
Therefore, screening of pregnant women for positive
HBsAg followed by appropriate immunizations of in-
fants, if needed, is crucial to avoid hepatitis B virus
transmission [4, 10, 16].
In an earlier investigation performed in Switzerland,
the prevalence of chronic hepatitis B infection in preg-
nant women was 0.5% [12]. In this current study in a
predominantly urban area of Switzerland, 1.2% of
pregnant women tested positive for HBsAg.
Surprisingly, but probably due to low numbers and/
or selection, none of 131 pregnant women originating
from Africa or Asia tested positive despite the fact that
hepatitis B prevalence rates are known to be high in
these areas.
While screening of pregnant women for HBsAg was
excellent in this investigation, compliance with immu-
noprophylaxis recommended in their oﬀspring in the
case of a positive result was concerning and put children
at unnecessary risk for acquisition of infection. Of
particular concern, one exposed child was found to be
chronically infected due to negligence of oﬃcial recom-
mendations which prompted counselling of the family
and notiﬁcation of the hospital’s malpractice insurance.
Approximately 8% of women admitted for delivery
had no previous HBsAg testing performed. Although
this rate is favourable compared with that from a study
in Germany, where 29% of the women had an unknown
HBsAg status at birth [9], the lack of speciﬁc recom-
mendations under such circumstances in Switzerland
creates problems in clinical management. Other
Fig. 1 Time points and doses of active immunisations in HBsAg
exposed infants
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countries, like Germany, recommend a ﬁrst dose of ac-
tive immunisation under such circumstances, followed
by passive immunisation up to 7 days after birth in case
the mother’s HBsAg test turns out positive [10]. The
American Academy of Pediatrics has published similar
recommendations [1] and in our opinion this should also
be considered in Switzerland. Of note, breast-feeding is
not a risk for hepatitis B infection in adequately im-
munised infants.
A further problem was identiﬁed in a preterm in-
fant, where active immunisation was delayed by mis-
take. Data from recent studies do in fact recommend
immediate immunisation of exposed infants regardless
of gestational age and comparable immune responses
have been documented in preterm and full-term in-
fants [4].
Finally, compliance with completion of the HBV
immunisation series and further serological testing was
not optimal in this investigation. Studies performed in
other countries revealed similar ﬁndings with good
compliance with administration of the ﬁrst dose of HBV
while infants are still in hospital, whereas only 65%–
91% of exposed infants received their second and third
doses [5, 8, 14, 15]. This clearly requires improvement,
which could easily be implemented by verbal and written
instructions to both the parents and the child’s paedia-
trician in private practice.
Based on the ﬁndings in this study, our institution has
optimised standard procedures and adequate conse-
quences have been taken. Other institutions may feel
encouraged to ensure that appropriate measurements for
prophylaxis of perinatal hepatitis B virus transmission
are being performed.
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